Several U.S. Food and Drug Administration-approvedATP-competitive small-molecule KIT kinase inhibitors have improvedthe outcome in KIT-driven cancers.10,19,22 However, these drugs vary in their ability to bindto oncogenic mutants. Here, KIT is linked to cancer.